For UK HealthTech companies
Your healthtech works, but without NHS champions, it stays invisible
The NHS is too fragmented for cold outreach alone to move deals forward. Without internal advocates who believe in your solution and carry it across departments, adoption stalls regardless of clinical merit.
Two minutes. Solva follows up with specific champion-building options.
- Pilot projects failing to scale beyond initial trials due to lack of internal buy-in
- HealthTech solutions being adopted by individual departments but not spreading across an entire Trust or private hospital group
- Sales cycles extending significantly beyond projections, consuming excessive resources
- Key decision-makers remaining unaware of a solution's benefits despite initial positive feedback from early adopters
- Inefficient deployment and integration of new technologies
- Increased burden on sales and account management teams to drive adoption
- Prolonged sales cycles leading to higher customer acquisition costs
- Increased marketing and advocacy spend with diminishing returns
- Delayed access to innovative solutions for patients in both NHS and private settings
- Slower improvement in patient outcomes due to underutilised technology
- Perception of a solution as difficult to implement or lacking widespread appeal
- Negative word-of-mouth within the healthcare community
The UK HealthTech sector faces challenges in fostering late-stage research and clinical studies within the country due to delays in NHS Trust approvals, indicating a broader difficulty in internal NHS advocacy for new technologies (KPMG, 2024)
Frequently asked questions
Why does this problem persist?
Without dedicated internal champions within the NHS, even effective healthtech solutions can struggle to gain visibility and word-of-mouth adoption. The fragmented nature of the NHS and limited resources for innovation advocacy make it challenging to cultivate and leverage these networks.
What is the cost of leaving it unaddressed?
The complex regulatory environment and NHS procurement policies extend time to market and increase development costs for HealthTech solutions, impacting profitability and scalability (KPMG, 2024)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.